HistoSonics’ Edison histotripsy system obtains CE mark

HistoSonics will now initiate a phased commercial rollout of its Edison system across European centres of excellence that specialise in liver tumour treatment. HistoSonics will now initiate a phased commercial rollout of its Edison system across European centres of excellence that specialise in liver tumour treatment. HistoSonics highlights that histotripsy may represent a suitable treatment option for liver tumour patients who are ineligible for surgery. Credit: crystal light/Shutterstock.com HistoSonics has secured a European CE mark for its histotripsy system Edison, setting the stage for the device’s commercialisation across the continent. Designed for the non-invasive destruction of liver tumours, HistoSonics’ Edison…

Source: Medical Device Network